Influence of calcium channel antagonists on nonsomatic signs of nicotine and D-amphetamine withdrawal in mice

Pharmacological Reports

Volumn 66, Issue 2, 2014, Pages 212-222

  Biała, Grazyna ^a   Polak, Piotr ^a   Michalak, Agnieszka ^a   Kruk Słomka, Marta ^a   Budzyńska, Barbara ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Calcium channel antagonists; D Amphetamine; Mice; Nicotine; Withdrawal

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DEXAMPHETAMINE; FLUNARIZINE; NICOTINE; NIMODIPINE; VERAPAMIL; CALCIUM; CALCIUM CHANNEL;

ADULT; ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; HOT PLATE TEST; HYPERALGESIA; MALE; MEMORY DISORDER; MOUSE; NOCICEPTIVE PAIN; NONHUMAN; PATHOPHYSIOLOGY; WITHDRAWAL SYNDROME; ANIMAL; DRUG EFFECTS; MEMORY; METABOLISM; NOCICEPTION; PHYSIOLOGY; PREVENTION AND CONTROL; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALS; ANXIETY; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DEPRESSION; DEXTROAMPHETAMINE; MEMORY; MICE; NICOTINE; NOCICEPTION; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84899627308     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.02.003     Document Type: Article

References (66)

1. Antkiewicz-Michaluk L, Michaluk J, Romaníska I, Vetulani J. Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology 1993;11:457-64.
2. Barr AM, Markou A. Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 2005;29:675-706. (Pubitemid 40755460)
3. Biala G, Budzynska B. Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur J Pharmacol 2006;537:85-93.
4. Biala G, Budzynska B. Calcium-dependent mechanisms of the reinstatement of nicotine conditioned place preference by drug priming in rats. Pharmacol Biochem Behav 2008;89:116-25.
5. Biala G, Kruk M. Calcium channel antagonists suppress cross-tolerance to the anxiogenic effects of D-amphetamine and nicotine in the mouse elevated plus maze. Prog Neuro-Psychopharmacol Biol Psychiatry 2008;32:54-61.
6. Biala G, Kruk M. Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep 2009;61:236-44.
7. Biala G, Kruk M, Budzynska B. Effects of the cannabinoid receptor ligands on anxiety-related effects of D-amphetamine and nicotine in the mouse elevated plus maze test. J Physiol Pharmacol 2009;60:113-22.
8. Biala G, Weglinska B. Blockade of the expression of mecamylamine- precipitated nicotine withdrawal by calcium channel antagonists. Pharmacol Res 2005;51:483-8. (Pubitemid 40321018)
9. Bressan RA, Crippa JA. The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. Acta Psychiatr Scand Suppl 2005;111:14-21. (Pubitemid 40780195)
10. Bruijnzeel AW, Zislis G, Wilson C, Gold MS. Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 2007;32: 955-63. (Pubitemid 46426186)
11. Budzynska B, Polak P, Biala G. Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm. Behav Brain Res 2012;216:144-50.
12. Chen Y, Yang C, Wang ZJ. Ca2+/calmodulin-dependent protein kinase IIa is required for the initiation and maintenance of opioid-induced hyperalgesia. J Neurosci 2010;30:38-46.
13. Coffey SF, Dansky BS, Carrigan MH, Brady KT. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep and withdrawal symptoms. Drug Alcohol Depend 2000;59:277-86. (Pubitemid 30254242)
14. Cryan JF, Gasparini F, van Heeke G, Markou A. Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today 2003;8:1025-34. (Pubitemid 38018809)
15. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2001;70:439-46. (Pubitemid 34131638)
16. Davis JA, Gould TJ. Hippocampal nAChRs mediate nicotine withdrawal-related learning deficits. Eur Neuropsychopharmacol 2009;19:551-61.
17. Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 2000;393:295-314. (Pubitemid 30193428)
18. D'Souza MS, Markou A. Neural substrates of psychostimulant withdrawalinduced anhedonia. Curr Top Behav Neurosci 2010;3:119-78.
19. Eddy NB, Leimbach D. Synthetic analgesic. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther 1953;107:385-93.
20. Fogari R, Zoppi A, Malamani GD, Corradi L. Effects of calcium channel blockers on cardiovascular responses to smoking in normotensive and hypertensive smokers. Int J Clin Pharmacol Res 1992;12:81-8.
21. Fukushiro DF, Mári-Kawamoto E, Aramini TCF, Saito LP, Costa JM, Josino FS, et al. Withdrawal from repeated treatment with amphetamine reduces novelty-seeking behavior and enhances environmental habituation in mice. Pharmacol Biochem Behav 2011;100:180-4.
22. Gould TJ, Portugal GS, André JM, Tadman MP, Marks MJ, Kenney JW, et al. The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. Neuropharmacology 2012;62:2118-25.
23. He J, Deng CY, Chen RZ, Zhu XN, Yu JP. Long-term potentiation induced by nicotine in CA1 region hippocampal slice is Ca(2+)-dependent. Acta Pharmacol Sin 2000;21:429-32. (Pubitemid 30304389)
24. Hoffmeister F, Benz U, Heise A, Krause HP, Neuser V. Behavioral effects of nimodipine in animals. Arzneimittelforschung 1982;32:347-60.
25. Holman RB. Biological effects of central nervous system stimulants. Addiction 1994;89:1435-41. (Pubitemid 24343902)
26. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007;9:315-27. (Pubitemid 46404264)
27. Isola R, Vogelsberg V, Wemlinger TA, Neff NH, Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Res 1999;850:189-96.
28. Jackson KJ, Damaj MI. L-Type calcium channel and calcium/calmodulin- dependent kinase II differentially mediate behaviors associated with nicotine withdrawal in mice. J Pharmacol Exp Ther 2009;330:152-61.
29. Jackson KJ, McIntosh JM, Brunzell DH, Sanjakdar SS, Damaj MI. The role of a6-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal. J Pharmacol Exp Ther 2009;33:1547-54.
30. Jacobsen LK, Mencl WE, Constable RT, Westerveld M, Pugh KR. Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. Psychopharmacology (Berl) 2007;193:557-66. (Pubitemid 47094373)
31. Kapur A, YeckelMF, Gray R, JohnstonD. L-Type calciumchannels are required for one form of hippocampal mossy fiber cLTP. J Neurophysiol 1998;79:2181-90. (Pubitemid 28183347)
32. Karler R, Turkanis SA, Partlow LM, Calder LD. Calcium channel blockers and behavioral sensitization. Life Sci 1991;49:165-70.
33. Kazda B, Garthoff HP, Krause K, Schlossmann F. Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 1982;32:331-8.
34. Kenny PJ, Markou A. Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav 2001;70:531-49. (Pubitemid 34131647)
35. Kiraly SJ, Ancill RJ, Dimitrova G. The relationship of endogenous cortisol to psychiatric disorder: a review. Can J Psychiatry 1997;42:415-20. (Pubitemid 27288391)
36. Koob GF. A role for brain stress systems in addiction. Neuron 2008;59:11-34. (Pubitemid 351905857)
37. Koob GF, Le Moal M. Addiction and the brain antireward system. Annu Rev Psychol 2008;59:29-53.
38. Lago JA, Kosten TR. Stimulant withdrawal. Addiction 1994;89:1477-81. (Pubitemid 24343908)
39. Le Foll B, Goldberg SR. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 2009;192:335-67.
40. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987;92:180-5. (Pubitemid 17072893)
41. Lu L, Grimm JW, Shaham Y, Hope BT. Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine self-administration in rats. J Neurochem 2003;85:1604-13. (Pubitemid 36702572)
42. Malin DH. Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav 2001;70:551-9. (Pubitemid 34131648)
43. McGregor C, Srisurapanont M, Jittiwutikarn J, Laobhripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction 2005;100:1320-9. (Pubitemid 41248073)
44. Mendrek A, Monterosso J, Simon SL, Jarvik M, Brody A, Olmstead R, et al. Working memory in cigarette smokers: comparison to non-smokers and effects of abstinence. Add Behav 2006;31:833-44.
45. Mizoguchi H, Ibi D, Takase F, Nagai T, Kamei H, Toth E, et al. Nicotine ameliorates impairment of working memory in methamphetamine-treated rats. Behav Brain Res 2011;220:159-63.
46. Murphy CA, Heidbreder C, Feldon J. Acute withdrawal from repeated cocaine treatment enhances latent inhibition of a conditioned fear response. Behav Pharmacol 2001;12:13-23. (Pubitemid 32202890)
47. Narita M, Matsumura Y, Ozaki S, Ise Y, Yajima Y, Suzuki T. Role of the calcium/calmodulin-dependent protein kinase II (CaMKII) in the morphine-induced pharmacological effects in the mouse. Neuroscience 2004;126:415-21. (Pubitemid 38780817)
48. Nawata Y, Kitaichi K, Yamamoto T. Increases of CRF in the amygdala are responsible for reinstatement of methamphetamine-seeking behavior induced by footshock. Pharmacol Biochem Behav 2012;101:297-302.
49. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997;278:58-63. (Pubitemid 27446271)
50. Nestler EJ, Carlezon Jr. WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-9. (Pubitemid 44192421)
51. Nordahl TE, Salo R, Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003;15:317-25. (Pubitemid 36999374)
52. Parsons LH, Koob GF, Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995;274:1182-91.
53. Porsolt RD, Le PM, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977;266:730-2. (Pubitemid 8073804)
54. Portugal GS, Kenney JW, Gould TJ. b2 Containing acetylcholine receptors mediate nicotine withdrawal deficits in learning. Neurobiol Learn Mem 2008;89:106-13.
55. Reichel CM, Ramsey LA, Schwendt M, McGinty JF, See RE. Methamphetamineinduced changes in the object recognition memory circuit. Neuropharmacology 2012;62:1119-26.
56. Scholl JL, Vuong SM, Forster GL. Chronic amphetamine treatment enhances corticotropin-releasing factor-induced serotonin release in the amygdala. Eur J Pharmacol 2010;644:80-7.
57. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, et al. Neurocognitive effects of methamphetamine: a critical review and metaanalysis. Neuropsychol Rev 2007;17:275-97. (Pubitemid 47498174)
58. Stolerman IP, Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci 1991;12:467-73.
59. Suzuki T, Ise Y, Maeda J, Misawa M. Mecamylamine-precipitated nicotinewithdrawal aversion in Lewis and Fisher 344 inbred rat strain. Eur J Pharmacol 1999;369:159-62. (Pubitemid 29129552)
60. Tonge SR. Noradrenaline and 5-hydroxytryptamine metabolism in six areas of rat brain during post-amphethamine depression. Psychopharmacologia 1974;38:181-6.
61. Vogel WH, Miller J, Waxman H, Gottheil E. Biochemical and behavioral changes in rats during and after chronic D-amphetamine exposure. Drug Alcohol Depend 1985;15:245-53. (Pubitemid 15031763)
62. Wilmouth CE, Spear LP. Withdrawal from chronic nicotine in adolescent and adult rats. Pharmacol Biochem Behav 2006;85:648-57. (Pubitemid 46097077)
63. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-92.
64. Wonnacott S. Presynaptic nicotinic ACh receptors. TrendsNeurosci 1997;20:92-8. (Pubitemid 27050704)
65. Zaniewska M, McCreary AC, Wydra K, Filip M. Effects of serotonin (5-HT)2 receptor ligands on depression-like behavior during nicotine withdrawal. Neuropharmacology 2010;58:1140-6.
66. Zaniewska M, Przegalinski E, Filip M. Nicotine dependence-human and animal studies, current pharmacotherapies and future perspectives. Pharmacol Rep 2009;61:957-65.